Moexipril and left ventricular hypertrophy

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 23-30

  Chrysant, George S ^a,c   Nguyen, P K ^b  

^a INTEGRIS Heart Hospital   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c NONE   (United States)

Author keywords

ACE inhibitor; Cardiovascular disease; Left ventricular hypertropy; Moexipril

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; LISINOPRIL; LOSARTAN; METOPROLOL; MOEXIPRIL; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; TRANDOLAPRIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; ELECTROCARDIOGRAPHY; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 34249860890     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Abernethy DR, Fox AAL, Stimpel M. 1995. Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained release varapamil. J Clin Pharmacol, 35:795-9.
2. Agabiti-Rosei E, Ambrosioni E, Pirelli, et al. 1999. Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension: MADAM study group. Eur J Clin Pharmacol, 55:185-9.
3. Barfour JA, Gos KL. 1995. Benazepril, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure. Drugs, 42:511-39.
4. Brilla CG, Maubara I, Weber KT. 1996. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-medicated regression of myocardial fibrosis. Hypertension, 28:269-74.
5. Chrysant SG. 1994. Antihypertensive effectiveness of low dose lisinopril-hydrochlorothiazide combinations: a large multicenter study. Arch Intern Med, 154:737-43.
6. Chrysant, SG. 1997. Perindopril/hydrochlorothiazide dose combination for the treatment of hypertension: a multicenter study. J Clin Pharmacol, 37:47-52.
7. Chrysant SG. 1998a. Vascular remodeling: the role of angiostensin-converting enzyme inhibitors. Am Heart J, 135:S21-S30.
8. Chrysant, SG. 1998b. Fixed low-dose drug combination for the treatment of hypertension. Arch Fam Med, 7:370-6.
9. Chrysant, SG Dunn M, Marples D, et al. 1983. Severe reversible azortemia from captopril therapy: report of three cases and review of the literature. Arch Intern Med, 143:437-41.
10. Chrysant SG, Fox AAL, Stimpel M. 1995. Comparison of moexipril, a new ACE inhibitor, to varapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hypertens, 8:418-21.
11. Chrysant, SG, Fagan T, Glazer R, et al. 1996. Effects of benazepril and hydrochlorothiadize, given alone and in low and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med, 5:17-24.
12. Chrysant SG, Stimpel M. 1998. Antihypertensive effectiveness of a very low fixed-dose comination of moexipril and hydrochlorothiazide. J Cardiovasc Pharmacol, 31:384-90.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 359:995-1003.
14. Devereux RB. 1995. Left ventricular geometry, pathophysiology and prognosis. J Am Coll Cardiol, 25:885-7.
15. Devereux RB, Dahlof B, Gerdts E, et al. 2004. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation, 110:1456-62.
16. Devereux RB, Roman MJ. 1993. Inter-relationships between hypertension, left ventricular hypertrophy and coronary heart disease. J Hypertens, 11:3-9.
17. Dickstein K, Aasland T, Ferrari P, et al. 1994. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. J Cardiovasc Pharmacol, 24:247-55.
18. Edling O, Bao G, Feelisch M, et al. 1995. Moexipril, a new angiotensin converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther, 275:854-63.
19. Frohlich ED, Apstein C, Chobanian AV, et al. 1992. The heart in hypertension. N Engl J Med, 327:998-1008.
20. Froshlich ED, Horinak S. 1991. Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension, 18(Suppl II):2-7.
21. Ghali JK, Liao Y, Cooper RS. 1998. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol, 31:1635-40.
22. Ghali JK, Liao Y, Simmons B, et al. 1992. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med, 117:831-6.
23. Gottdiener JS, Reda DJ, Massie BM, et al. 1997. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation, 95:2007-14.
24. Grass GM, Morehead W. 1989. Evidence for site specific absorption of a nove ACE inhibitor. Pharm Res, 6:759-65.
25. Grohe C, Kahlert S, Lobbert K, et al. 1997. Effects of moexiprilat on estrogen-stimulated cardiac fibroblast growth. Br J Pharmacol, 121:1-5.
26. Haider AW, Larson MG, Benjamin EJ, et al. 1998. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol, 32:1454-62.
27. Hoefle ML, Klutchko S. 1982. Substituted acyl derivatives of 1, 2, 3, 4 tetrahydroquinoline 3-carboxylic acids. US Pat, 944-9.
28. Knutsen R, Knutsen S, Curb JD, et al. 1988. The predictive value of resting electrocardiograms for 12-year incidence of coronary heart disease in the Honolulu Heart Program. J Clin Epidemiol, 41:293-302.
29. Koren MJ, Devereux RB, Casale PN, et al. 1991. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med, 114:345-52.
30. Krumholz HM, Larson M, Levy D. 1995. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol, 25:879-84.
31. Klucthko S, Blankely CJ, Fleming RW, et al. 1986. Synthesis of the novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationship for non-sulfhydryl and sulthydryl types. J Med. Chem, 29:1953-961.
32. Lancaster SG, Todd PA. 1998. Moexipril: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs, 35:646-67.
33. Levy D, Anderson KM, Savage DD, et al. 1988. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med, 108:7-13.
34. Levy D, Salomon M, D'Agostino RB, et al. 1994. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation, 90:1786-93.
35. Liebson PR, Grandits GA, Dianzumba S, et al. 1995. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation, 91:698-706.
36. Lucas CD, Darga LL, Fox AAL, et al. 1995. A study of the efficacy and safety of moexipril in mild to moderate hypertension. Am J Ther, 2:886-92.
37. Moser M, Hebert PR. 1996. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol, 27:1214-18.
38. Neaton JD, Grimm RJ Jr, Stamler J, et al. 1993. Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA, 270:713-24.
39. Persson B, Stimpel M. 1996. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol, 50:259-64.
40. Pfeffer MA, Braunwald E, Moye LA, et al. 1992. Effect of captopril on morality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med, 327:669-77.
41. Phillips RA, Diamond JA. 1999. Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension. In Oparil S, Weber MA (eds). Hypertension: A Companion to Brenner and Rector's The Kidney. Philadelphia: W.B. Saunders Company. p. 244-77.
42. Rosendorff C. 1996. The rennin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol, 28:803-12.
43. Rumble JR, Komers R, Cooper ME. 1996. Kinins or nitric oxide, or both are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens, 14:601-7.
44. The SOLVD Investigators. 1991. Effects on enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 325:293-302.
45. Sayegh F, Topouchian J, Hlawaty M, et al. 2005. Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients. Am J Ther, 12:3-8.
46. Schlaich MP, Schmieder RE. 1998. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach. J Hypertens, 11:1394-404.
47. Schmieder RE, Martus P, Klingbeil A. 1996. Reversal of left ventricular hypertrophy in essential hypertension. JAMA, 275:1507-13.
48. Singhvi SM, Duchin KC, Morrison RA, et al. 1998. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol, 25:9-15.
49. Song JC, White CM. 2002. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors. An update. Clin Pharmacokinet, 41:207-24.
50. Spinar J, Vitovec J. 2005. MORE-moexipril and regression of left ventricular hypertrophy in combination therapy. A multicentric open label clinical trial. Int J Cardiol, 100:199-206.
51. Stimpel M, Bonn R, Koch BK, et al. 1995. Pharmacology and clinical use of the new ACE inhibitor moexipril. Cardiovasc Drug Rev, 13:211-29.
52. Stimpel M, Koch B. 1996. Antihypertensive treatment in postmenopausal women with hypertension and obesity: moexipril versus atenolol [abstract]. Am J Hypertens, 9:175A.
53. Stimpel M, Koch B, Jansen T, et al. 1996a. Moexrpril versus captopril in patients with mild to moderate hypertension. J Cardiovasc Pharmacol, 28:769-73.
54. Stimpel M, Koch B, Dickstein K. 1996b. Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. Cardiology, 87:313-18.
55. Stimpel M, Koch B. 1997. Antihypertensive treatment with moexipril plus HCTZ vs. metrprolol plus HCTZ in patients with mild to moderate hypertension. J Hum Hypertens, 11:133-7.
56. Stimpel M, Koch B, Oparil S. 1998. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology, 89:271-6.
57. Stimpel M, Koch B, Weber MA. 1998. Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. Maturitas, 30:69-77.
58. Strauss HM, Zhu YC, Redlich T, et al. 1994. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk, 1:255-62.
59. Thurmann PA, Kenedi P, Schmidt A, et al. 1998. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation, 98:2037-42.
60. Verdecchia P, Schillaci G, Borgioni C, et al. 1995. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol, 25:879-84.
61. Verdecchia P, Schillaci G, Borgioni C, et al. 1998. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation, 97:48-54.
62. White WB, Fox AAL, Stimpel M. 1994. Long term efficacy and safety of moexipril in the treatment of hypertension. J Hum Hypertens, 8:917-921.
63. White, WB, Koch B, Stimpel M. 1997. Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. Am J Ther, 4:123-9.
64. White WB, Stimpel M. 1995. Long-term efficacy and safety of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. J Hum Hypertens, 9:879-84.